Ustekinumab
Yıl: 2022 Cilt: 56 Sayı: 1 Sayfa Aralığı: 48 - 51 Metin Dili: İngilizce DOI: 10.4274/turkderm.galenos.2022.63139 İndeks Tarihi: 18-07-2022
Ustekinumab
Öz: Ustekinumab is an antagonistic human monoclonal immunoglobulin G1 antibody that targets p40, a common subunit of interleukin-12 (IL-12)
and IL-23. In clinical trials, 66-81% of the patients using ustekinumab achieved a PASI75 response. Its long drug survival time has been found
remarkable in real-world experiences. Other advantages of ustekinumab include ease of use in obese patients as its dose can be adjusted
according to body weight and its administration every 12 weeks in the maintenance period.
Anahtar Kelime: Ustekinumab
Öz: Ustekinumab interlökin-12 (IL-12) ve IL-23’ün ortak alt birimi p40’ı hedef alan immünoglobulin G1 yapısında bir monoklonal antikordur. Klinik
araştırmalarda PAŞİ75 yanıtı sağlanan hasta oranları %66 ile 81 arasında değişmektedir. Gerçek yaşam çalışmalarında ise uzun ilaç sağkalım
süresi ile öne çıkmaktadır. Vücut ağırlığına göre doz seçimi yapıldığı için obez hastalarda kullanım kolaylığı ve idame döneminde 12 haftada bir
uygulanması ustekinumabın diğer avantajlarıdır
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Kimball AB, Papp KA, Wasfi Y, et al.: Long term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study. J Eur Acad Dermatol Venereol 2013;27:1535-45.
- 2. Nast A, Boehncke WH, Mrowietz U, et al.: S3-Guidelines on the treatment of psoriasis vulgaris (English version) Update. J Dtsch Dermatol Ges 2012;10(Suppl2):1-95.
- 3. Croxtall JD: Ustekinumab: a review of its use in the management of moderate to severe plaque psoriasis. Drugs 2011;71:1731-53.
- 4. Luo J, Wu SJ, Lacy ER, et al.: Structural basis for the dual recognition of IL-12 and IL-23 by ustekinumab. J Mol Biol 2010;402:797-812.
- 5. Smith CH, Anstey AV, Barker JN, et al.: British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009. Br J Dermatol 2009;161:987-1019.
- 6. Langley R, et al.: Poster presented at the EADV. Prague, Czech Republic 2012;P976.
- 7. Nast A, Gisondi P, Ormerod AD, et al.: European S3-Guidelines on the systemic treatment of psoriasis vulgaris - Update 2015 - Short versionEDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol 2015;29:2277-94.
- 8. Leonardi CL, Kimball AB, Papp KA, et al.: Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008;371:1665-74.
- 9. Papp KA, Langley RG, Lebwohl M, et al.: Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebocontrolled trial (PHOENIX 2). Lancet 2008;371:1675-84.
- 10. Griffiths CE, Strober BE, van de Kerkhof P, et al.: Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 2010;362:118- 28.
- 11. Kimball AB, Gordon KB, Fakharzadeh S, et al.: Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis: results from the PHOENIX 1 trial through up to 3 years. Br J Dermatol 2012;166:861-72.
- 12. Clemmensen A, Spon M, Skov L, Zachariae C, Gniadecki R: Responses to ustekinumab in the anti-TNF agent-naïve vs. anti-TNF agent-exposed patients with psoriasis vulgaris. J Eur Acad Dermatol Venereol 2011;25:1037-40.
- 13. Takahashi N, Noda S, Taniguchi T, Adachi M: Efficacy comparison of ustekinumab between anti-tumor necrosis factor- drug-naïve and anti-tumor necrosis factor- drug-resistant Japanese psoriasis cases. Int J Dermatol 2015;54:1194-8.
- 14. Landells I, Marano C, Hsu MC, et al.: Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study. J Am Acad Dermatol 2015;73:594- 603.
- 15. Warren RB, Smith CH, Yiu ZZ, et al.: Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol 2015;135:2632-40.
- 16. Gniadecki R, Bang B, Bryld LE, Iversen L, Lasthein S, Skov L: Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris. Br J Dermatol 2015;172:244-52.
- 17. No authors listed: Abstracts of the Third International Congress on Psoriasis. July 1-4, 2010. Paris, France. J Eur Acad Dermatol Venerol 2010;24(Suppl4):1-83.
- 18. Hugh J, Van Voorhees AS, Nijhawan RI, et al.: From the Medical Board of the National Psoriasis Foundation: the risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies. J Am Acad Dermatol 2014;70:168-77.
- 19. Papp K, Gottlieb AB, Naldi L, et al.: Safety surveillance for ustekinumab and other psoriasis treatments from the psoriasis longitudinal assessment and registry (PSOLAR). J Drugs Dermatol 2015;14:706-14.
- 20. Meng Y, Dongmei L, Yanbin P, et al.: Systematic review and meta-analysis of ustekinumab for moderate to severe psoriasis. Clin Exp Dermatol 2014;39:696-707.
- 21. Molina-Leyva A, Husein-Elahmed H, Naranjo-Sintes R, Ruiz-Carrascosa JC: Safety and effectiveness of ustekinumab for treatment of moderate to severe psoriasis: a prospective study in a clinical setting. J Drugs Dermatol 2014;13:971-4.
- 22. Egeberg A, Ottosen MB, Gniadecki R, Broesby-Olsen S, Dam TN, Bryld LE: Safety, efficacy and drug survival of biologics and biosimilars for moderateto-severe plaque psoriasis. Br J Dermatol 2018;178:509-19.
- 23. Menter A, Papp KA, Gooderham M, et al.: Drug survival of biologic therapy in a large, disease-based registry of patients with psoriasis: Results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) J Eur Acad Dermatol Venereol 2016;30:1148-58.
| APA | borlu m (2022). Ustekinumab. , 48 - 51. 10.4274/turkderm.galenos.2022.63139 |
| Chicago | borlu murat Ustekinumab. (2022): 48 - 51. 10.4274/turkderm.galenos.2022.63139 |
| MLA | borlu murat Ustekinumab. , 2022, ss.48 - 51. 10.4274/turkderm.galenos.2022.63139 |
| AMA | borlu m Ustekinumab. . 2022; 48 - 51. 10.4274/turkderm.galenos.2022.63139 |
| Vancouver | borlu m Ustekinumab. . 2022; 48 - 51. 10.4274/turkderm.galenos.2022.63139 |
| IEEE | borlu m "Ustekinumab." , ss.48 - 51, 2022. 10.4274/turkderm.galenos.2022.63139 |
| ISNAD | borlu, murat. "Ustekinumab". (2022), 48-51. https://doi.org/10.4274/turkderm.galenos.2022.63139 |
| APA | borlu m (2022). Ustekinumab. Türkderm Türk deri hastalıkları ve frengi arşivi, 56(1), 48 - 51. 10.4274/turkderm.galenos.2022.63139 |
| Chicago | borlu murat Ustekinumab. Türkderm Türk deri hastalıkları ve frengi arşivi 56, no.1 (2022): 48 - 51. 10.4274/turkderm.galenos.2022.63139 |
| MLA | borlu murat Ustekinumab. Türkderm Türk deri hastalıkları ve frengi arşivi, vol.56, no.1, 2022, ss.48 - 51. 10.4274/turkderm.galenos.2022.63139 |
| AMA | borlu m Ustekinumab. Türkderm Türk deri hastalıkları ve frengi arşivi. 2022; 56(1): 48 - 51. 10.4274/turkderm.galenos.2022.63139 |
| Vancouver | borlu m Ustekinumab. Türkderm Türk deri hastalıkları ve frengi arşivi. 2022; 56(1): 48 - 51. 10.4274/turkderm.galenos.2022.63139 |
| IEEE | borlu m "Ustekinumab." Türkderm Türk deri hastalıkları ve frengi arşivi, 56, ss.48 - 51, 2022. 10.4274/turkderm.galenos.2022.63139 |
| ISNAD | borlu, murat. "Ustekinumab". Türkderm Türk deri hastalıkları ve frengi arşivi 56/1 (2022), 48-51. https://doi.org/10.4274/turkderm.galenos.2022.63139 |
